Tirapibep

Tirapibep is a programmed cell death protein 1 (PD-1) blocking monoclonal antibody identified in clinical trial contexts, specifically associated with trial ChiCTR2500112026. In this study, it is investigated as part of a neoadjuvant regimen for locally advanced or oligometastatic prostate cancer, combined with fasudil hydrochloride (a ROCK inhibitor) and androgen deprivation therapy (ADT). The treatment aims to improve pathological complete response (pCR) and biochemical progression-free survival (bPFS) prior to radical prostatectomy. While the name 'Tirapibep' is used in certain trial-related descriptions, the drug officially registered for the corresponding trial ID (ChiCTR2500112026) in the Chinese Clinical Trial Registry is **tislelizumab**. The name 'Tirapibep' appears to be an erroneous label or a phonetic mangling of 'tislelizumab' or 'toripalimab', potentially confounded by the name 'tirapazamine' (a chemically distinct hypoxia-activated cytotoxin) in some source documents.

Other names

tislelizumabtirapazamine